Antibiotic Treatment Strategies for Pediatric Cystic Fibrosis Exacerbations
This study is looking at two different ways to treat lung flare-ups (pulmonary exacerbations) in children with cystic fibrosis (CF). One group will start preselected oral antibiotics right away for 14 days, along with increased airway clearance. The other group will also increase airway clearance, but will only start preselected oral antibiotics later if their symptoms get worse or don't improve. The study wants to see how these two approaches affect your child's lung function over one year, measured by a breathing test called ppFEV1. Children aged 3 to 18 with a confirmed CF diagnosis can join. The study is currently unclear on its recruitment status and aims to enroll 430 participants.
- Study design
- This is a multicenter, open-label, randomized controlled trial. It will compare two treatment strategies in 430 participants.
- What's involved
- Participants will be followed for 12 months. They will increase airway clearance and may take oral antibiotics for 14 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year after treatment to measure changes in lung function.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
At a glance
Conditions
Where it's being run
33 sites across 26 statesStudy leadership
- D. B. Sanders, MD, MS · PRINCIPAL_INVESTIGATOR · Indiana University
- Margaret Rosenfeld, MD, MPH · PRINCIPAL_INVESTIGATOR · Seattle Children's Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- One-year change in pulmonary function by spirometry-measured ppFEV11 year
Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease.